Trial Profile
Verteporfin photodynamic therapy for central serous chorioretinopathy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Verteporfin (Primary)
- Indications Central serous chorioretinopathy
- Focus Therapeutic Use
- 27 May 2016 New trial record